By Alex Morgan, Senior AI Tools Analyst
Last updated: May 08, 2026

Why a Biotech’s Secrecy on Equity Could Signal a Funding Crisis Ahead

In recent weeks, discussions surrounding a biotech company’s Series A funding round have raised alarms. The firm, reportedly, has chosen not to disclose equity offerings, a choice that is not just curious but potentially catastrophic. This lack of transparency arrives against a backdrop where a staggering 70% of startups fail to secure follow-on funding, raising questions about how secrecy could be perpetuating a culture of distrust in biotech. The implications for investor confidence and overall sector health are significant.

But why should we care? The dynamics of equity visibility are pivotal—especially now, as transparency could be the only currency left to attract floundering funds in a dwindling market. If the sector continues this obfuscation, we may witness a crisis in biotech funding as severe as that faced by the infamous Theranos.

What Is Equity Transparency?

Equity transparency refers to the practice of openly disclosing the ownership stakes and financial terms associated with investments in a startup. This is not merely a best practice; it is increasingly becoming a litmus test for trustworthiness in the biotech field. Investors want to know what they’re buying into, much like a homebuyer would want a full inspection report before making a significant purchase. Currently, with a lack of clarity from many biotech firms, some investors may be stepping back before even entering the bidding war. Understanding the importance of transparency has become crucial, as outlined in 5 Game-Changing Rules for IndieHackers to Revive Quality Discussion.

Why is this important? In an investment landscape where credibility can tip the balance, avoiding transparency could leave startups on shaky ground. After all, potential investors opt for companies that communicate their financial realities clearly. A refusal to disclose key terms could signal trouble ahead.

How Equity Transparency Works in Practice

To illustrate the importance of equity transparency, consider two contrasting examples in the biotech industry: Theranos and Moderna.

Theranos

The now-defunct Theranos serves as a stark warning on the dangers of secrecy. The company touted revolutionary blood-testing technology but avoided disclosing critical operational data. This culture of secrecy ultimately led to its downfall, resulting in massive investor losses and a federal indictment of founder Elizabeth Holmes. Experts estimate that investors lost nearly $900 million, demonstrating how a lack of transparency can obliterate credibility and trust.

Moderna

In sharp contrast, Moderna thrived during its Series A funding rounds, partly due to its transparent communication strategies. Early investors had clear visibility on equity stakes and a straightforward discussion about milestones and uses of funds. As a result, the company attracted more investment early on, securing a whopping $11.1 billion in revenue in 2022 from its COVID-19 vaccine alone. Moderna’s success showcases that even in a crowded marketplace, clarity can facilitate investor relationships and lead to financial triumph, a principle that aligns with the insights discussed in 10 Remarkable Non-AI Projects That Are Reshaping Startups in 2023.

Startup Genome Report

According to a recent survey by Startup Genome, over 53% of startups that fail to disclose key financial terms face a staggering 25% lower chance of securing follow-on investments. The data is unambiguous: keeping equity details under wraps could very well diminish a startup’s chances in an already competitive space.

Top Tools and Solutions

To navigate this complex landscape of equity transparency, startups might consider leveraging technology for better communication and data transparency. Here are some tools that can assist:

• ThorData — A business data and analytics platform that helps startups track their financial metrics, making sure they can present the data clearly to potential investors.

• Syllaby — This tool enables the creation of AI videos and social media automation, ideal for startups looking to pitch in a more engaging format.

• Lusha — A B2B contact data platform that can assist startups in connecting with potential investors more effectively.

• Amplemarket — AI-driven sales automation software that helps track investor leads and improve engagement.

Disclosure: Some links in this article may be affiliate links. We may earn a small commission at no extra cost to you. This does not influence our recommendations.

Common Mistakes and What to Avoid

Falling into the pitfalls of opacity can be detrimental. Here’s how top startups have failed by avoiding equity disclosures:

Mistake 1: Concealing Equity Percentages

A notable biotech startup, aiming to emulate Theranos, kept its equity percentages hidden during their fundraising phase. Investors quickly lost interest, leading the co.